GT Trademark

Trademark Overview

On Tuesday, March 12, 2013, a trademark application was filed for GT with the United States Patent and Trademark Office. The USPTO has given the GT trademark a serial number of 85873670. The federal status of this trademark filing is REGISTERED AND RENEWED as of Monday, May 13, 2024. This trademark is owned by Galectin Therapeutics Inc.. The GT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, compounds for use in the treatment of nonalcoholic steatohepatitis, fibrosis, inflammatory and autoimmune disorders, neoplastic conditions, cancer, liver fibrosis, kidney fibrosis, lung fibrosis and/or heart fibrosis
gt

General Information

Serial Number85873670
Word MarkGT
Filing DateTuesday, March 12, 2013
Status800 - REGISTERED AND RENEWED
Status DateMonday, May 13, 2024
Registration Number4492470
Registration DateTuesday, March 4, 2014
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, September 10, 2013

Trademark Statements

Description of MarkThe mark consists of the stylized version of the letters "G" and "T" in white. The area in the upper left and lower right portions of the mark are red. The area in the lower left portion of the mark is black. The area in the upper right portion of the mark is gray.
Goods and ServicesPharmaceutical preparations, namely, compounds for use in the treatment of nonalcoholic steatohepatitis, fibrosis, inflammatory and autoimmune disorders, neoplastic conditions, cancer, liver fibrosis, kidney fibrosis, lung fibrosis and/or heart fibrosis
Pseudo MarkGALECTIN THERAPEUTICS
Indication of Colors claimedThe color(s) red, black and gray is/are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, March 16, 2013
Primary Code005
First Use Anywhere DateThursday, June 27, 2013
First Use In Commerce DateThursday, June 27, 2013

Trademark Owner History

Party NameGalectin Therapeutics Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNorcross, GA 30071
Party NameGalectin Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorcross, GA 30071
Party NameGalectin Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorcross, GA 30071

Trademark Events

Event DateEvent Description
Friday, March 15, 2013NEW APPLICATION ENTERED
Tuesday, March 19, 2013NOTICE OF PSEUDO MARK E-MAILED
Friday, June 21, 2013ASSIGNED TO EXAMINER
Sunday, June 23, 2013NON-FINAL ACTION WRITTEN
Sunday, June 23, 2013NON-FINAL ACTION E-MAILED
Sunday, June 23, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, July 3, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 9, 2013ASSIGNED TO LIE
Tuesday, July 30, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 6, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, August 21, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, March 16, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 16, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 16, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 10, 2013PUBLISHED FOR OPPOSITION
Tuesday, September 10, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 5, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, November 11, 2013TEAS STATEMENT OF USE RECEIVED
Monday, December 9, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 20, 2014ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 28, 2014NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, March 4, 2014REGISTERED-PRINCIPAL REGISTER
Monday, December 3, 2018TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, December 3, 2018REVIEW OF CORRESPONDENCE COMPLETE - POWER OF ATTORNEY ENTERED
Monday, November 11, 2013USE AMENDMENT FILED
Wednesday, December 18, 2013STATEMENT OF USE PROCESSING COMPLETE
Monday, January 27, 2014LAW OFFICE REGISTRATION REVIEW COMPLETED
Monday, March 4, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, April 8, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, August 13, 2019TEAS SECTION 8 & 15 RECEIVED
Tuesday, August 13, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 20, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, October 1, 2019POST REGISTRATION ACTION MAILED - SEC. 8 & 15
Wednesday, April 1, 2020TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Friday, June 5, 2020REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Friday, June 5, 2020NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, April 6, 2020POST REGISTRATION ACTION MAILED - SEC. 8 & 15
Friday, June 5, 2020TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Saturday, March 4, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, January 26, 2024TEAS SECTION 8 & 9 RECEIVED
Monday, May 13, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, May 13, 2024REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Monday, May 13, 2024REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Monday, May 13, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED

Related Keywords

fibrosis conditions neoplastic cancer liver heart lung kidney disorders inflammatory